ANA-12

ANA-12
Clinical data
ATC code	None;
Identifiers
	IUPAC name N-[2-[(2-oxoazepan-3-yl)carbamoyl]phenyl]-1-benzothiophene-2-carboxamide;
CAS Number	219766-25-3 ;
PubChem CID	2799722;
ChemSpider	2078460;
UNII	54S4JPT8JX;
CompTox Dashboard (EPA)	DTXSID501045818 ;
ECHA InfoCard	100.229.925
Chemical and physical data
Formula	C22H21N3O3S
Molar mass	407.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCNC(=O)C(C1)NC(=O)C2=CC=CC=C2NC(=O)C3=CC4=CC=CC=C4S3;
	InChI InChI=1S/C22H21N3O3S/c26-20(25-17-10-5-6-12-23-21(17)27)15-8-2-3-9-16(15)24-22(28)19-13-14-7-1-4-11-18(14)29-19/h1-4,7-9,11,13,17H,5-6,10,12H2,(H,23,27)(H,24,28)(H,25,26); Key:TUSCYCAIGRVBMD-UHFFFAOYSA-N;

ANA-12 is a selective, small-molecule non-competitive antagonist of TrkB, the main receptor of brain-derived neurotrophic factor (BDNF).^[1] ANA-12 was originally discovered and developed by Cazorla M. and colleagues at Université Paris and Inserm in 2011.^[1] The compound crosses the blood-brain-barrier and exerts central TrkB blockade, producing effects as early as 30 minutes (~400 nM) and as long as 6 hours (~10 nM) following intraperitoneal injection in mice.^[1] It blocks the neurotrophic actions of BDNF without compromising neuron survival.^[1]

Clinical data

ATC code	None
Identifiers
IUPAC name N-[2-[(2-oxoazepan-3-yl)carbamoyl]phenyl]-1-benzothiophene-2-carboxamide
CAS Number	219766-25-3^Y
PubChem CID	2799722
ChemSpider	2078460
UNII	54S4JPT8JX
CompTox Dashboard (EPA)	DTXSID501045818
ECHA InfoCard	100.229.925
Chemical and physical data
Formula	C₂₂H₂₁N₃O₃S
Molar mass	407.49 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1CCNC(=O)C(C1)NC(=O)C2=CC=CC=C2NC(=O)C3=CC4=CC=CC=C4S3
InChI InChI=1S/C22H21N3O3S/c26-20(25-17-10-5-6-12-23-21(17)27)15-8-2-3-9-16(15)24-22(28)19-13-14-7-1-4-11-18(14)29-19/h1-4,7-9,11,13,17H,5-6,10,12H2,(H,23,27)(H,24,28)(H,25,26) Key:TUSCYCAIGRVBMD-UHFFFAOYSA-N